Filing Flows › Comparisons › ATYR vs CRDF
aTYR Pharma vs Cardiff Oncology: ATYR and CRDF compared
aTYR Pharma is the larger company: $190K of revenue in its latest quarter (Q3 2025) against $104K for Cardiff Oncology (Q2 2026).
Where the money goes: ATYR and CRDF
aTYR Pharma (ATYR) · Q3 2025
aTYR Pharma, Q3 2025: revenue $190K, net loss $25.7M, operating cash flow −$20.5M. The chart follows the revenue to costs, profit and cash.
Cardiff Oncology (CRDF) · Q2 2026
Cardiff Oncology, Q2 2026: revenue $104K (-14% year over year), net loss $9.2M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
| aTYR Pharma (ATYR) | Cardiff Oncology (CRDF) | |
|---|---|---|
| Latest quarter | Q3 2025 | Q2 2026 |
| Revenue | $190K | $104K |
| Revenue growth, Y/Y | — | -14% |
| Operating margin | n/m | n/m |
| Net earnings | −$25.7M | −$9.2M |
| Operating cash flow | −$20.5M | −$11.8M |
Questions
Which is bigger, aTYR Pharma or Cardiff Oncology?
aTYR Pharma is the larger company: $190K of revenue in its latest quarter (Q3 2025) against $104K for Cardiff Oncology (Q2 2026).
More: aTYR Pharma earnings · how aTYR Pharma makes money · Cardiff Oncology earnings · how Cardiff Oncology makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2025; 10-Q filed Aug 11, 2026). Fiscal quarters can end on different dates. Not investment advice.